A serotonin 2A receptor agonist is a psychoactive substance whose effects are primarily or substantially produced by activating the serotonin 5-HT2A receptor in cortical neurons, generating the altered perception, mood, and cognition collectively termed psychedelic.[1] The class is defined by this shared molecular target rather than by any single chemical scaffold, and membership is broad — three structurally unrelated chemical families converge on the same receptor.
The grouping spans the tryptamines (DMT, psilocin, 4-AcO-DMT), the lysergamides (LSD, 1P-LSD, AL-LAD), and the phenethylamines (mescaline, 2C-B, DOI), along with the extraordinarily potent N-benzyl derivatives such as 25I-NBOMe. Despite this structural diversity the members produce qualitatively similar perceptual effects through the same receptor.[1]
The class produces a dose-dependent trajectory: at low exposure, mild sensory enhancement and loosened associative thought; at high exposure, complex visual hallucinations, ego dissolution, and mystical-type experiences.[2] Members are used in traditional ceremonial contexts (around ayahuasca and psilocybin mushrooms in particular), as research probes of cortical function, in contemporary clinical trials for depression and related conditions, and recreationally. The experience is highly sensitive to set and setting.
Pharmacology
Most members of the class converge on a single endpoint: activation of the 5-HT2A receptor on the apical dendrites of layer V pyramidal neurons in the medial prefrontal cortex and other association cortices.[2]
These pyramidal neurons are the principal output cells of cortical circuits, and their 5-HT2A-mediated excitation drives a surge of glutamate release that disrupts normal thalamocortical gating — the filtering mechanism that ordinarily structures perception.
| Chemical family | Representative members | How it engages the shared target |
|---|---|---|
| Tryptamines | DMT, psilocin, 4-AcO-DMT | Indole scaffold overlapping the endogenous ligand serotonin; less selective for 5-HT2A, with appreciable activity at 5-HT1A, 5-HT2C, and sigma-1 receptors[3] |
| Lysergamides | LSD, AL-LAD, ETH-LAD | Rigid ergoline scaffold with the broadest receptor profile in the class — dopaminergic and adrenergic activity alongside multiple serotonin subtypes; an extracellular-loop "lid" prolongs receptor dwell time[1] |
| Phenethylamines | mescaline, 2C-B, DOI | 2,5-dimethoxyphenethylamine pharmacophore conferring the highest 5-HT2A selectivity in the class[3] |
| N-benzyl derivatives | 25I-NBOMe, 25C-NBOMe, 25B-NBOMe | N-(2-methoxybenzyl) or N-(2-hydroxybenzyl) modification of 2C-x phenethylamines, producing sub-nanomolar to picomolar receptor affinity and an exceptionally narrow safety margin[4] |
At the molecular level, 5-HT2A activation canonically couples through Gαq/11 to phospholipase C, but the receptor signals through multiple parallel cascades and different agonists engage them to different degrees — a phenomenon called biased agonism.[5]
The hallucinogenic response is associated specifically with one subset of these pathways; non-hallucinogenic 5-HT2A agonists such as lisuride bind the same receptor without producing psychedelic effects. A second key finding is the 5-HT2A/mGlu2 receptor heteromer, a functional complex in cortical neurons that hallucinogens preferentially engage.[6] The shared endpoint matters more for class behaviour than the precise route each chemotype takes to reach it.
A significant subset of members are prodrugs that are weakly active at the receptor themselves but are hydrolyzed in vivo to an active 5-HT2A agonist parent — the 4-acetoxy tryptamines, the acyl-LSD analogues such as 1P-LSD and ALD-52, and similar compounds. Their inclusion is mechanistically appropriate: the pharmacological action is still 5-HT2A agonism, one metabolic step removed.
Substances
The class is illustrated by members spanning all three chemical families and several functional sub-groups.
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| LSD | Lysergamide | The prototypical long-duration psychedelic; among the highest agonist affinities of the classical members |
| Psilocin | Tryptamine | The active form of psilocybin and the most clinically studied member of the class |
| DMT | Tryptamine | Endogenous; prototypical rapid-onset, very short-duration psychedelic when smoked or vaporized |
| Mescaline | Phenethylamine | The prototypical phenethylamine psychedelic, derived from peyote and related cacti |
| 2C-B | Phenethylamine (2C-x) | Widely studied member of the 2C series, with a milder effect profile than LSD or psilocin |
| DOI | Phenethylamine (DOx) | Highly selective 5-HT2A full agonist used as a research radioligand; very long duration |
| 25I-NBOMe | N-benzyl phenethylamine | Among the most potent members; active in microgram quantities and the most acutely dangerous in the class (see Safety) |
| 1P-LSD | Lysergamide prodrug | Representative of the acyl-LSD prodrug family; hydrolyzes in vivo to release LSD |
| Ayahuasca | Plant preparation | DMT plus a monoamine oxidase inhibitor; orally active and prolonged by the MAOI component |
| LSA | Naturally occurring lysergamide | A weaker, naturally occurring lysergamide found in morning glory seeds and related plants |
These members differ widely in potency, onset, and duration, but each produces qualitatively similar perceptual effects through the same receptor. A small subset of members — including 5-MeO-DMT, MDA, and the entactogenic benzofurans 5-APB and 6-APB — carry 5-HT2A agonism as a secondary mechanism alongside a dominant action (5-HT1A agonism or monoamine release); their psychedelic character is contributory rather than defining.
Subjective Effects
The subjective trajectory of the class scales with 5-HT2A receptor occupancy and is qualitatively consistent across chemical families, with duration and sensory emphasis varying by compound.[1]
| Exposure | Characteristic effects |
|---|---|
| Low | Mild enhancement of sensory vividness, subtle closed-eye geometric patterns, enhanced colour saturation, loosening of associative thought, heightened emotional responsiveness, and altered sense of time; nausea is common at onset |
| Moderate–high | Complex visual hallucinations progressing from closed-eye imagery to open-eye distortions and morphing, synesthesia, abstract and non-linear cognition, marked emotional intensity (positive or negative), and amplified introspection |
| High | Ego dissolution — temporary loss of the ordinary self/environment boundary — and mystical-type experiences involving profound feelings of unity, awe, or cosmic significance; auditory phenomena are common, while fully formed auditory hallucinations are less typical than visual ones |
The defining practical feature of the class is its sensitivity to set and setting: the same compound at the same dose can produce an experience ranging from revelatory to severely distressing depending on psychological state, environment, and social support.
This context-dependence distinguishes the class from most other pharmacological categories, and is the central reason that preparation and a calm setting are emphasised in both traditional ceremonial use and contemporary clinical research.
Duration varies widely across members — from very brief (smoked DMT) through intermediate (most tryptamines and lysergamide prodrugs) to very long (the DOx phenethylamines) — reflecting pharmacokinetic differences in absorption, metabolism, and receptor dwell time rather than any difference in mechanism.[1]
Safety
Risk profile
The defining acute risk of the class is psychological: anxiety, paranoia, panic, and severely distressing experiences ("bad trips") occur in a meaningful fraction of high-dose sessions, particularly in unprepared users or unsupportive settings.In one large survey of difficult psilocybin mushroom experiences, roughly two-fifths of respondents rated the episode among the five most challenging experiences of their lives, and about a quarter reported adverse reactions persisting beyond a day.[7]
The class also carries a documented risk of precipitating or worsening psychosis in individuals with a personal or family history of schizophrenia or bipolar disorder; this contraindication is consistent across all members.[1]
A minority of users develop hallucinogen persisting perception disorder (HPPD): persistent or recurrent visual disturbances (visual snow, geometric patterns, tracers, derealization) that continue after the acute experience has ended. Reported prevalence varies widely with definition and survey method, and severe chronic forms appear rare; transient flashbacks are more common and typically brief.[8] Prior psychiatric conditions, concurrent use of multiple substances, and use of high-potency or novel compounds (notably the NBOMe series) appear to elevate risk.
The N-benzyl derivative series (25I-NBOMe, 25C-NBOMe, 25B-NBOMe and the corresponding NBOH compounds) presents a qualitatively different acute danger profile from the classical members. Their sub-nanomolar receptor affinity means the active dose is exceptionally small, and documented case series describe tachycardia, hypertension, hyperthermia, agitation, rhabdomyolysis, seizures, and death following modest exposure.[4]
Sympathomimetic and cardiac (5-HT2B) effects compound the receptor potency, and the margin between a psychedelic dose and a toxic dose is narrow in a way that the classical members are not. The very long-acting DOx phenethylamines carry a related but distinct concern: prolonged vasoconstriction and sympathomimetic strain sustained over many hours, during which any complication — cardiovascular, thermoregulatory, or psychiatric — is also sustained.
Combining a class member with a monoamine oxidase inhibitor substantially raises serotonergic load and plasma levels of tryptamine members — the basis on which ayahuasca and changa are formulated, and a distinct risk tier from members taken alone.
Combinations with other serotonergic agents (SSRIs, SNRIs, other psychedelics) carry a theoretical serotonin-syndrome risk that is poorly characterised at typical psychedelic doses but is best avoided, particularly with the high-potency members.
Tolerance & dependence
Tolerance to 5-HT2A agonists develops rapidly and is among the most pronounced of any psychoactive class. Repeated use on consecutive days progressively attenuates effects within several days, driven by 5-HT2A receptor downregulation in the frontal cortex; sensitivity recovers over a roughly one- to two-week period of abstinence.[9] Cross-tolerance is universal across the class: a person tolerant to LSD will have markedly reduced sensitivity to psilocin, mescaline, and other members simultaneously, but the cross-tolerance does not extend to dissociatives, entactogens, or other pharmacological classes.[9]
Physical dependence on the class has not been demonstrated and there is no recognised withdrawal syndrome. Systematic evaluations under the US Controlled Substances Act framework conclude that classical 5-HT2A agonists produce only weak and inconsistent reinforcing effects, are poorly self-administered in animal models, and do not produce a withdrawal syndrome in humans.[10]
The rapid tolerance acts as a natural brake on compulsive use, since escalating frequency does not yield sustained reward. Problematic psychological patterns of use occur in some individuals — DSM-5 recognises "other hallucinogen use disorder" as a diagnosis — but this is qualitatively different from the physical dependence that characterises depressants and opioids.
Recovery
Because the class does not produce physical dependence or a withdrawal syndrome, there is no need for medically supervised detoxification, and recovery from problematic use is generally an integration and behavioural-support process rather than a pharmacological one.The more common after-effect is a difficult or destabilising acute experience: speaking with a psychedelic-integration therapist, a peer-support service, or a mental-health clinician familiar with these compounds can help process and resolve such experiences. For persistent perceptual disturbances or psychiatric symptoms emerging after use, evaluation by a clinician is appropriate. For anyone with a personal or family history of psychotic or bipolar illness, the safer path is to avoid the class entirely.
Recovery resources, crisis lines, and support pathways → View all
Members
references
- [1]
- [2] ^abVollenweider, F.X. and Kometer, M. (2010) The neurobiology of psychedelic drugs: implications for the treatment of mood disorders — Nature Reviews Neuroscience doi:10.1038/nrn2884
- [3] ^abNichols, D.E. (2012) Structure-activity relationships of serotonin 5-HT2A agonists — WIREs Membrane Transport and Signaling doi:10.1002/wmts.42
- [4] ^abGee P, Schep LJ, Jensen BP, Moore G, Barrington S (2016) Case series: toxicity from 25B-NBOMe--a cluster of N-bomb cases. — Clinical Toxicology doi:10.3109/15563650.2015.1115056
- [5] ^López-Giménez, J.F. and González-Maeso, J. (2018) Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways — Current Topics in Behavioral Neuroscience doi:10.1007/7854_2017_478
- [6] ^González-Maeso, J. and Weisstaub, N.V. and Zhou, M. and Chan, P. and Ivic, L. and Ang, R. and Lira, A. and Bradley-Moore, M. and Ge, Y. and Zhou, Q. and Sealfon, S.C. and Gingrich, J.A. (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior — Neuron doi:10.1016/j.neuron.2007.01.008